Last edited by Natilar
Friday, May 8, 2020 | History

4 edition of The strategic use and potential demand for an HIV vaccine in Southern Africa found in the catalog.

The strategic use and potential demand for an HIV vaccine in Southern Africa

Chris Desmond

The strategic use and potential demand for an HIV vaccine in Southern Africa

by Chris Desmond

  • 350 Want to read
  • 18 Currently reading

Published by World Bank in Washington, D.C .
Written in English

    Places:
  • Africa, Southern.
    • Subjects:
    • HIV (Viruses) -- Africa, Southern.,
    • AIDS (Disease) -- Africa, Southern.,
    • AIDS vaccines -- Africa, Southern.

    • Edition Notes

      StatementChristopher Desmond and Robert Greener.
      SeriesPolicy research working paper ;, 2977, Policy research working papers (Online) ;, 2977.
      ContributionsGreener, Robert., World Bank.
      Classifications
      LC ClassificationsHG3881.5.W57
      The Physical Object
      FormatElectronic resource
      ID Numbers
      Open LibraryOL3285174M
      LC Control Number2003615326

        “A safe and effective HIV vaccine could help bring about a durable end to the HIV/AIDS pandemic and is particularly needed in southern Africa, where HIV is .   Emerging markets such as China and India are expected to generate significant demand for HIV vaccines during the period, As per the MRFR analysis, the global HIV vaccines .

      Like smallpox and polio vaccines, a preventive HIV vaccine could help save millions of lives. Developing safe, effective, and affordable vaccines that can prevent HIV infection is the NIH’s highest HIV research priority given its game-changing potential for controlling and ultimately ending the HIV/AIDS pandemic.   By engineering an on/off switch into a weakened form of HIV, University of Nebraska-Lincoln researchers have enhanced the safety and effectiveness of a potential vaccine for .

      This approach to developing an HIV vaccine is based on theory and involves establishing an understanding of the immune response to HIV infection and finding ways to generate and enhance that response through vaccination. Some strategies aim to prevent HIV infection via antibodies, while others strive to generate a protective cellular response.   According to a report, $ million was spent on HIV vaccine research in And to date, more than 40 potential vaccines have been tested. There’s been slow progress toward a Author: Christine Case-Lo.


Share this book
You might also like
The holly branch

The holly branch

Economic crises

Economic crises

Developing social policy in conditions of rapid change

Developing social policy in conditions of rapid change

man of double deed.

man of double deed.

1978 census of agriculture, preliminary report, Canyon County, Idaho.

1978 census of agriculture, preliminary report, Canyon County, Idaho.

Our next move in politics, by the vampires of the round table

Our next move in politics, by the vampires of the round table

The Wrong People

The Wrong People

One-parent families today

One-parent families today

Starbrat.

Starbrat.

drawings of Toulouse-Lautrec

drawings of Toulouse-Lautrec

ow irrigation

ow irrigation

Evaluation of CEER productivity, 1979-80 to 1987-88

Evaluation of CEER productivity, 1979-80 to 1987-88

Productivity through work innovations

Productivity through work innovations

African fairy tales

African fairy tales

The legion of time.

The legion of time.

The strategic use and potential demand for an HIV vaccine in Southern Africa by Chris Desmond Download PDF EPUB FB2

The Strategic Use and Potential Demand for an HIV Vaccine in Southern Africa Christopher Desmond Health Economics and HIV/AIDS Research Division, University of Natal Durban, South Africa [email protected] Robert Greener Botswana Institute for Development Policy Analysis Gaborone, Botswana [email protected] HIV prevalence in Southern Africa is the highest in the world and the impact of HIV/AIDS in the region are devastating at all levels of society, including the wider economy.

Government response has lagged behind the pace of the epidemic, but programs are now beginning to focus on a broad range of interventions to combat its further spread and to mitigate its impact.

Desmond, Christopher*Greener, Robert, "The strategic use and potential demand for an HIV vaccine in Southern Africa," Policy Research Working Paper SeriesThe World Bank. Handle: RePEc:wbk:wbrwpsCited by: 4. for and strategic use of an HIV-1 vaccine in the four southern Indian states of Andhra Pradesh, Karnataka, Maharashtra, and Tamil Nad u.

It also discusses potential strategies for. Strategic use and potential demand for an HIV vaccine in Southern Africa.

Washington, D.C.: World Bank, Development Research Group, Public Services, [] (OCoLC) Desmond and Greener investigate the issues around the targeting of an eventual HIV vaccine.

There is at present no vaccine against HIV. Although several candidates are in the trial stage, it is not likely that a vaccine effective against the sub-type of the virus prevalent in Southern Africa. HIV prevalence in Southern Africa is the highest in the world and the impact of HIV/AIDS in the region are devastating at all levels of society, including the wider economy.

Government response has lagged behind the pace of the epidemic, but programs. The strategic use and potential demand for an HIV vaccine in Southern Africa (English) Abstract. HIV prevalence in Southern Africa is the highest in the world and the impact of HIV/AIDS in the region are devastating at all levels of society, including the wider by: 4.

The purpose of this paper is to investigate the issues around the targeting of an eventual HIV vaccine. There is at present no vaccine against HIV. Although several candidates are in the trial stage, it is not likely that a vaccine effective against the sub-type of the virus prevalent in Southern Africa will be available for years.

Based on evidence of adoption of other vaccines in India, current levels of spending on them and coverage of prevention programs targeting both high- and low-risk groups, Seshadri, Subramaniyam, and Jha assess the potential demand for and strategic use of an HIV-1 vaccine in the four southern Indian states of Andhra Pradesh, Karnataka, Maharashtra, and Tamil Nadu.

Get this from a library. The strategic use and potential demand for an HIV vaccine in Southern Africa. [Chris Desmond; Robert Greener; World Bank.] -- HIV prevalence in Southern Africa is the highest in the world and the impact of HIV/AIDS in the region are devastating at all levels of society, including the wider economy.

Government response has. The authors investigate the issues around the targeting of an eventual HIV vaccine. There is at present no vaccine against HIV. Although several candidates are in the trial stage, it is not likely that a vaccine effective against the sub-type of the virus prevalent in Southern Africa will be available for : Christopher Desmond and Robert Greener.

The Strategic Use and Potential Demand for an HIV Vaccine in Southern Africa Desmond, Christopher; Greener, Robert () HIV prevalence in Southern Africa is the highest in the world and the impact of HIV/AIDS in the region are devastating at all.

Robert GREENER of Oxford Policy Management, Oxford | Read 24 publications | Contact Robert GREENER The strategic use and potential demand for an HIV vaccine in Southern Africa. Global estimates. At the global level, three estimates of demand for an HIV vaccine have been made to date.

The first focuses on the number of vaccination courses required by developing countries for national HIV vaccination programs in the first five years after vaccine launch []. (A “course” refers to two or more vaccinations administered to the same individual several months apart, as Cited by: 5.

Based on evidence of adoption of other vaccines in India, current levels of spending on them and coverage of prevention programs targeting both high- and low-risk groups, Seshadri, Subramaniyam, and Jha assess the potential demand for and strategic use of an HIV-1 vaccine in the four southern Indian states of Andhra Pradesh, Karnataka.

This vaccine contained sequences of the HIV sub-type C virus that is most commonly found in southern Africa and used a different dosing schedule designed to produce stronger responses to the vaccine. The study found that the vaccine produced strong antibody responses to HIV envelope proteins.

Why We Don’t Have An HIV Vaccine, And How We Can Develop One 23 Global demand for an HIV vaccine over the next three decades could cost the dominant strain in the southern cone of Africa Cited by: 8.

This economic evaluation aims to support policy-making on the combined use of pre-exposure prophylaxis (PrEP) with HIV vaccines in development by evaluating the potential cost-effectiveness of implementation that would support the design of clinical trials for the assessment of combined product safety and efficacy.

The target study population is a cohort of men who have sex with men (MSM) in Cited by: 6. • Challenges of multi-pharma (component) HIV vaccine, varying manufacturing commitment • Potential licensure in South Africa in • Pox-protein Public Private Partnership (P5) Roadmap working group planning for potential efficacy and futility scenarios • P5 Global Access Committee set up to develop a vaccine access plan if vaccine.

These results from a detailed individual-based simulation model of the potential effects of a partially effective HIV vaccine on epidemics in southern Africa, in the context of assumed continued expansion of ART use, suggests that even a vaccine with 30% preventative efficacy could make a substantial difference in the rate with which HIV Cited by: The projected demand for an HIV vaccine as well as the general nature of the vaccine market suggests slim profit potential.

The countries most in need of the vaccine are precisely those which have the least ability to pay: low- to middle-income by: 4.HIV Infections 33 million million people living with HIV million million Remarkable scale up of treatment; however, doesn’t solve problem.

Lifetime treatment required and for every (1) person put on treatment, (2) are newly infected. THE WORLD NEEDS AN HIV VACCINE HIV continues to devastate. 32 million File Size: 1MB.